Announcements Trials
Browse Landscape

Phase

Phase 3 6Phase 2 5Phase 1/2 2Phase 1 2Phase NA 1Phase EARLY_PHASE1 1Phase 4 1Phase 2/3 1

Status

Completed 16Unknown 6Recruiting 6Active not recruiting 4Terminated 3Withdrawn 1Suspended 1

Sponsor Class

INDUSTRY 3OTHER 1NIH 1NETWORK 1

Study Type

Interventional 6

Sponsor

Cancer Type

Lymphoid 5Other hematologic neoplasm 2

Conditions

Precursor B-Cell Lymphoblastic Leukemia-Lymphoma 1Lymphoma, Large B-Cell, Diffuse 1Lymphoma, Follicular 1Lugano Classification Limited Stage Hodgkin Lymphoma AJCC v8 1Leukemia, Lymphocytic, Chronic, B-Cell 1Leukemia, Biphenotypic, Acute 1Hepatectomy 1Burkitt Lymphoma 1

Interventions

Carboplatin 98Cisplatin 95pembrolizumab 90Gemcitabine 81Paclitaxel 80Docetaxel 73Capecitabine 64Oxaliplatin 53Specimen Handling 52Fluorouracil 52Magnetic Resonance Spectroscopy 50Bevacizumab 49Radiotherapy 48Dexamethasone 45Cyclophosphamide 44Leucovorin 39Drug Therapy 39Irinotecan 37Doxorubicin 36Pemetrexed 35Injections 30Trastuzumab 28Vincristine 27Rituximab 27Radiosurgery 25Prednisone 25Etoposide 25130-nm albumin-bound paclitaxel 25Radiation 24Letrozole 24

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

6 trials
RecentStart dateEnrollment
Phase 3 × Recruiting × Methylprednisolone × Clear all
NCT05675410 2026-06-03

A Study to Compare Standard Therapy to Treat Hodgkin Lymphoma to the Use of Two Drugs, Brentuximab Vedotin and Nivolumab

National Cancer Institute (NCI)

Phase 3 Recruiting
1,875 enrolled
Lymphoid

Lugano Classification Limited Stage Hodgkin Lymphoma AJCC v8

NCT06717347 2026-05-29

MK-2140-010

Merck Sharp & Dohme LLC

Phase 3 Recruiting
1,046 enrolled
Lymphoid

Lymphoma, Large B-Cell, Diffuse

NCT06091254 2026-05-19

OLYMPIA-1

Regeneron Pharmaceuticals

Phase 3 Recruiting
822 enrolled
Lymphoid

Lymphoma, Follicular

NCT06970743 2026-05-11

CaDAnCe-303

BeOne Medicines

Phase 3 Recruiting
150 enrolled
LymphoidOther hematologic neoplasm

Leukemia, Lymphocytic, Chronic, B-Cell

NCT03959085 2026-05-05

Inotuzumab Ozogamicin and Post-Induction Chemotherapy in Treating Patients With High-Risk B-ALL, Mixed Phenotype Acute Leukemia, and B-LLy

Children's Oncology Group

Phase 3 Recruiting
5,951 enrolled
LymphoidOther hematologic neoplasm

Burkitt Lymphoma, Precursor B-Cell Lymphoblastic Leukemia-Lymphoma, Leukemia, Biphenotypic, Acute

NCT07507643 2026-04-02

A Study of Methylprednisolone in People Having Liver Surgery

Memorial Sloan Kettering Cancer Center

Phase 3 Recruiting
750 enrolled

Hepatectomy

Data powered by HemOnc (CC BY 4.0) Colophon âš¡